English English | 中文 中文

Chronic Diseases and Translational Medicine

Chronic Diseases and Translational Medicine (CDTM)is a quarterly peer-reviewed and open access journal, dedicated to advancing knowledge and practice in all areas of chronic diseases (cardiovascular, neoplastic, neurological, respiratory, endocrine or renal diseases) and translational medicine and promoting the interactions between basic and clinical research practitioners and physicians. CDTM is part of Chinese Medical Association (CMA)’s Journals family. The CMA journals are the most widely read, cited, and influential medical journals in China. CDTM benefits from exceptional knowledge, experience, and resources of CMA accumulated throughout its more than 100-year history. 

CDTM has a strong editorial board consisting of 104 selected, highly qualified experts from 13 countries which ensures the quality and credibility of the papers as well as of the journal itself. All submissions to the journal CDTM undergo double-blind peer review by a minimum of two qualified reviewers. Peer reviewers are chosen at a global level based on their research interests and their expertise in the research area. The 98 reviewers of CDTM in 2018 came from 28 countries (regions) including China, United States, United Kingdom, France, Italy, Canada, Netherlands, Switzerland, Austria, etc. An extensive and rigorous peer review process by prestigious experts guarantees that all articles meet the high standards of CDTM publication.

Until now, three volumes of CDTM have been published and highly regarded by researchers in this field. Impressively, our usage from ScienceDirect has been increasing substantially in the past four years, reaching a total of 177,502 views by the end of 2018. CDTM boasts thousands of readers from over 90 countries (regions), with American readers accounting for the largest proportion (5.927%), followed by Chinese (4.213%) and British (1.9%) readers. In addition, citations of CDTM articles by SCI-indexed journals have been constantly on the rise since its inception. The impact factor of CDTM is estimated to be 1.290 in 2018 and expected to exceed 2 in 2019.

Our acceptance for inclusion in PubMed/PubMed Central in 2017 represents a tremendous step forward in improving the visibility of articles published in CDTM and increasing the attractiveness of the journal for authors and readers. Up to now, CDTM has been indexed in the following databases: PubMed, PubMed Central, ScienceDirect, DOAJ, Google Scholar, Chinese Science Citation Database (CSCD), China Core Journal Alternative Database, China Open Access Journals (COAJ), Ulrich's Periodicals Directory.

We strongly encourage researchers in all branches of chronic diseases and translational medicine to submit your manuscripts to CDTM to benefit from a quick review process, no publication fees, open access, and indexing in major scientific databases including PubMed and PubMed Central. We receive manuscripts electronically via the CDTM online submission system (https://www.evise.com/profile/#/CDTM/login). Via the homepage of this journal, you will be guided stepwise through the creation and uploading of various files. 

We look forward to your contributions. Please feel free to contact us if you have any questions.

E-mail: weipeifang@cma.org.cn, cdtm@cma.org.cn

Tel: 86-10-85158260

Fax: 86-10-85158188


Share this page: